Efficacy and Safety of Mizolastine in Seasonal Allergic Rhinitis

Leynadier, F.; Bousquet, Jean; Murrieta, M.; Attali, P

doi:10.1016/s1081-1206(10)63417-5

Cited by 47 publications

(30 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The study showed that all doses of levocetirizine were well tolerated and signifi cantly superior to placebo in reducing the severity of sneezing, rhinorrhea, nasal pruritus, and ocular pruritus, which was recorded as the refl ective Total Four-Symptom Score (T4SS) in a dose-dependent manner. The 5-mg dose showed an optimal therapeutic index [33]. Similarly, the effi cacy of levocetirizine was demonstrated in children 6 to 12 years old with SAR over 6 weeks [34].…”

Section: Levocetirizinementioning

confidence: 81%

“…Levocetirizine, 5 mg once daily, is effective in treating SAR and PAR in adults and children older than 6 years of age [33][34][35][36]. One study evaluated the effect of treatment with 2.5-, 5-, or 10-mg levocetirizine tablets or placebo once daily for 2 weeks on severity of nasal and ocular symptoms in 470 adults with SAR to grass and/or weed pollen [33].…”

Section: Levocetirizinementioning

confidence: 99%

“…One study evaluated the effect of treatment with 2.5-, 5-, or 10-mg levocetirizine tablets or placebo once daily for 2 weeks on severity of nasal and ocular symptoms in 470 adults with SAR to grass and/or weed pollen [33]. The study showed that all doses of levocetirizine were well tolerated and signifi cantly superior to placebo in reducing the severity of sneezing, rhinorrhea, nasal pruritus, and ocular pruritus, which was recorded as the refl ective Total Four-Symptom Score (T4SS) in a dose-dependent manner.…”

Section: Levocetirizinementioning

confidence: 99%

See 2 more Smart Citations

Update on prescription and over-the-counter histamine inverse agonists in rhinitis therapy

DuBuske

Kowal²

2009

Curr Allergy Asthma Rep

View full text Add to dashboard Cite

Allergic rhinitis (AR) is associated with histamine-mediated physiologic events. The currently used histamine antagonists are all inverse agonists that bind and inactivate histamine H1 receptors. Second-generation antihistamines are much more H1-receptor selective with less central nervous system penetration than first-generation agents. Antihistamines typically are more effective in seasonal than perennial AR and do not demonstrate significant relief of nasal congestion. The recent availability of some second-generation antihistamines as over-the-counter products clearly places them as the preferred first-line treatment for mild to moderate AR based on safety when compared with first-generation over-the-counter antihistamines. The remaining prescription-only second-generation antihistamines, fexofenadine, desloratadine, and levocetirizine, all have unique attributes. Antihistamines in oral, intranasal, or intraocular formulations will likely remain among the mainstays of allergy therapeutics.

show abstract

Section: Levocetirizinementioning

confidence: 81%

Section: Levocetirizinementioning

confidence: 99%

Section: Levocetirizinementioning

confidence: 99%

See 1 more Smart Citation

Update on prescription and over-the-counter histamine inverse agonists in rhinitis therapy

DuBuske

Kowal²

2009

Curr Allergy Asthma Rep

View full text Add to dashboard Cite

show abstract

“…Overall severity has usually been assessed by the sum or mean sum of the major nasal scores, total nasal plus nonnasal symptom scores, or composites of major nasal and nonnasal symptoms. Visual analogue scales [14][15][16] and QOL questionnaires [17] are recommended for this purpose. Standardizing overall rhinitis severity is a problem yet to be solved.…”

Section: Literature Review: Grading Nasal Symptom Severity In Allergimentioning

confidence: 99%

Grading the severity of allergic rhinitis for treatment strategy and drug study purposes

Okuda

2001

Curr Allergy Asthma Rep

View full text Add to dashboard Cite

Grading the severity of rhinitis symptoms is essential for the evaluation of drug efficacy. However, a uniform grading system has not been standardized. A review of 44 journal articles and symposia from Japan, Copenhagen, and the World Health Organization indicates major differences among systems. All except the World Health Organization used a sum of rhinitis scores. The lack of standardization limits comparisons of subjective symptom changes after comparable treatments. Corrective measures include the use of evidence-based definitions of independent nasal symptoms, avoidance of biases in evaluation, and establishment of international consensus for a standardized scale in this era of globalization.

show abstract

“…Levocetirizine (XYZAL; UCB Pharma, Brussels, Belgium) is an oral, nonsedating H 1 -antihistamine that proved to be significantly effective in improving symptoms in patients with allergic rhinitis; it presents a good safety profile [3][4][5][6][7][8] and, for all these pharmacologic characteristics, is highly indicated as a first-line treatment in subjects with persistent allergic rhinitis (PER). The XYZAL in Persistent Rhinitis Trial (XPERT) is a remarkable study published in 2004, 9 providing different clinical, HRQoL, and pharmacoeconomic assessments, applied over the long term, and using electronic diary cards, to evaluate the efficacy of levocetirizine in both HRQoL and economic aspects.…”

mentioning

confidence: 99%

Persistent Allergic Rhinitis and the XPERT Study

Rogkakou

Villa

Garelli

et al. 2011

World Allergy Organization Journal

View full text Add to dashboard Cite

Allergic rhinitis (AR) is a chronic disease with an increasing trend in most of the Western Countries. It may significantly impair the individual quality of life (QoL) and also represents a social burden for its economic costs. Levocetirizine (XYZAL; UCB Pharma) as a second generation, nonsedating H1-antihistamine, has been shown to be clinically effective in patients with AR in different randomized controlled trials. The XPERT (XYZAL in Persistent Rhinitis Trial) is the first large, long-term clinical study involving patients with persistent rhinitis as defined by ARIA (Allergic Rhinitis and its Impact on Asthma). The XPERT was a 6-month double-blind, placebo-controlled, multicenter, multinational trial in 551 subjects. Adults with persistent rhinitis sensitized to both grass pollen and house dust mites were randomized to receive levocetirizine 5 mg/d or placebo. Two primary objectives were considered: comparison of the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) overall score and Total 5 Symptoms Score (rhinorrhea, sneezing, nasal congestion, and nasal and ocular pruritus) (T5SS) between active and control group over a period of 4 weeks. As secondary endpoints, similar evaluations at 1 week and 3, 4, 5, and 6 months, summary scores for a general health status questionnaire (Medical Outcomes Survey Short Form 36), comorbidities, pharmacoeconomic and safety evaluations. Levocetirizine significantly improved both the RQLQ overall score and the T5SS from week 1 to 6 months (P Ͻ.001). Medical Outcomes Survey Short Form 36 summary scores were also improved in the group treated with levocetirizine with respect to placebo. Treatment cessation because of lack of efficacy, comorbidities, and overall costs of disease, and comorbidities per working patient per month (160.27 vs 108.18) were lower in the levocetirizine group. In conclusion, levocetirizine resulted to improve the quality of life and the symptoms related to AR and also to reduce the overall costs of the disease after 6 months treatment.

show abstract

Efficacy and Safety of Mizolastine in Seasonal Allergic Rhinitis

Cited by 47 publications

References 7 publications

Update on prescription and over-the-counter histamine inverse agonists in rhinitis therapy

Update on prescription and over-the-counter histamine inverse agonists in rhinitis therapy

Grading the severity of allergic rhinitis for treatment strategy and drug study purposes

Persistent Allergic Rhinitis and the XPERT Study

Contact Info

Product

Resources

About